Processing Phage Therapy Requests in a Brussels Military Hospital: Lessons Identified

Djebara, Sarah; Maussen, Christiane; Vos, Daniël De; Merabishvili, Maya; Damanet, Benjamin; Pang, Kim Win; Leenheer, Peggy De; Strachinaru, Isabella; Soentjens, Patrick; Pirnay, Jean‐Paul

doi:10.3390/v11030265

Cited by 72 publications

(68 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following this report, phage therapy has been used in specific situations as an Emergency Investigational New Drug therapy to treat multidrug‐resistant bacteria . Belgium has been implementing a magistral phage framework that has allowed the use of tailor‐made phage therapy in a number of patients in the Queen Astrid military hospital in Brussels . Recently, the PhagoBurn trial, a randomised, controlled, double‐blind phase 1/2 trial, studied the efficacy and safety of the PP1131 phage cocktail against Pseudomonas aeruginosa in infected burn wounds.…”

Section: Phage Therapy In Humansmentioning

confidence: 99%

“…69 Belgium has been implementing a magistral phage framework that has allowed the use of tailor-made phage therapy in a number of patients in the Queen Astrid military hospital in Brussels. 70 Recently, the PhagoBurn trial, a randomised, controlled, double-blind phase 1/2 trial, studied the efficacy and safety of the PP1131 phage cocktail against…”

Section: Phag E Ther Apy In H Uman Smentioning

confidence: 99%

See 1 more Smart Citation

Review article: bacteriophages in gastroenterology—from biology to clinical applications

Sabino

Hirten

Colombel

2019

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background The gut microbiota plays an important role in the pathogenesis of several gastrointestinal diseases. Its composition and function are shaped by host‐microbiota and intra‐microbiota interactions. Bacteriophages (phages) are viruses that target bacteria and have the potential to modulate bacterial communities. Aims To summarise phage biology and the clinical applications of phages in gastroenterology Methods PubMed was searched to identify relevant studies. Results Phages induce bacterial cell lysis, integration of viral DNA into the bacteria and/or coexistence in a stable equilibrium. Bacteria and phages have co‐evolved and their dynamic interactions are yet to be fully understood. The increasing need to modulate microbial communities (e.g., gut microbiota, multidrug‐resistant bacteria) has been a strong stimulus for research in phages as an antibacterial therapy. In gastroenterology, phage therapy has been mainly studied in infectious diseases such as cholera. However, it is currently being explored in several other circumstances such as treating Clostridioides difficile colitis, targeting adherent‐invasive Escherichia coli in Crohn's disease or eradicating Fusobacterium nucleatum in colorectal cancer. Overall, phage therapy has a favourable and acceptable safety profile. Presently, trials with phage therapy are ongoing in Crohn's disease. Conclusions Phage therapy is a promising therapeutic tool against pathogenic bacteria in the fields of infectious diseases and gastroenterology. Randomised, placebo‐controlled trials with phage therapy for gastroenterological diseases are ongoing.

show abstract

Section: Phage Therapy In Humansmentioning

confidence: 99%

Section: Phag E Ther Apy In H Uman Smentioning

confidence: 99%

Review article: bacteriophages in gastroenterology—from biology to clinical applications

Sabino

Hirten

Colombel

2019

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Detailed results for the treatment are yet to be published, however, the general outcome proved to be positive. Scientists from the QAMH stress that in nearly all cases bacteriophages were administered along with other antimicrobials, like antibiotics (Djebara et al ).…”

Section: Introductionmentioning

confidence: 99%

Therapeutic bacteriophages as a rescue treatment for drug‐resistant infections – anin vivostudies overview

Kwiatek

Parasion²,

Nakonieczna

2019

J Appl Microbiol

View full text Add to dashboard Cite

Summary Bacteriophages, highly prevalent in all environments, have found their use in medicine as an alternative or complement to antibiotics. The therapeutic use of bacteriophages was particularly popular in the 1920s and 1930s, until the discovery and introduction of antibiotics. Due to the dynamic growth of antibiotic resistance among bacterial strains, numerous international institutions (such as the FDA) have declared the search for novel treatment modalities to be of the highest priority. To date, bacteriophage therapy has not been registered for general use in Western countries. The regulation of biological medicinal products (within medicinal product regulation) does not contain a specific documentation frame for bacteriophages (only for vaccines, blood derived products, etc.) which, as active substances, need to meet specific requirements. Recently, the FDA allowed bacteriophage therapy to be used in the United States, via the Emergency Investigational New Drug scheme; clinical trials to compare the safety and efficacy of bacteriophage therapy are also permitted. To date, several therapeutic products of this type have made it to phase I or II; some clinical programmes have also been completed. This article cites numerous animal model studies and registered clinical trials, showing the safety and effectiveness of bacteriophage therapy, including infections caused by bacterial strains resistant to antibiotic treatment.

show abstract

“…Since 2007, phage therapy has been permitted for the treatment of bacterial infections in the Queen Astrid Military Hospital in Brussels, Belgium, under the umbrella of the Declaration of Helsinki (article §37) established by the World Medical Association. According to an article from 2018, external requests for phage therapy in this hospital have significantly increased in the last two years [127]. Phagoburn was a European Research & Development project funded by the European Commission in 2013 and its clinical trial (NCT02116010) ended in 2017.…”

Section: Clinical Phage Therapy Trials On Woundsmentioning

confidence: 99%

Bacteriophages for Chronic Wound Treatment: From Traditional to Novel Delivery Systems

Pinto

Cerqueira

Bañobre-Lópes

et al. 2020

Viruses

View full text Add to dashboard Cite

The treatment and management of chronic wounds presents a massive financial burden for global health care systems, with significant and disturbing consequences for the patients affected. These wounds remain challenging to treat, reduce the patients' life quality, and are responsible for a high percentage of limb amputations and many premature deaths. The presence of bacterial biofilms hampers chronic wound therapy due to the high tolerance of biofilm cells to many firstand second-line antibiotics. Due to the appearance of antibiotic-resistant and multidrug-resistant pathogens in these types of wounds, the research for alternative and complementary therapeutic approaches has increased. Bacteriophage (phage) therapy, discovered in the early 1900s, has been revived in the last few decades due to its antibacterial efficacy against antibiotic-resistant clinical isolates. Its use in the treatment of non-healing wounds has shown promising outcomes. In this review, we focus on the societal problems of chronic wounds, describe both the history and ongoing clinical trials of chronic wound-related treatments, and also outline experiments carried out for efficacy evaluation with different phage-host systems using in vitro, ex vivo, and in vivo animal models. We also describe the modern and most recent delivery systems developed for the incorporation of phages for species-targeted antibacterial control while protecting them upon exposure to harsh conditions, increasing the shelf life and facilitating storage of phage-based products. In this review, we also highlight the advances in phage therapy regulation.

show abstract

Processing Phage Therapy Requests in a Brussels Military Hospital: Lessons Identified

Cited by 72 publications

References 13 publications

Review article: bacteriophages in gastroenterology—from biology to clinical applications

Review article: bacteriophages in gastroenterology—from biology to clinical applications

Therapeutic bacteriophages as a rescue treatment for drug‐resistant infections – anin vivostudies overview

Bacteriophages for Chronic Wound Treatment: From Traditional to Novel Delivery Systems

Contact Info

Product

Resources

About